Sudarshan Pharma Industries Ltd shareholders have approved the migration of the company's equity shares from the SME Platform of BSE Limited to the Main Board of BSE Limited. The resolution, passed via a postal ballot conducted from 26 May 2026 to 24 June 2026, received 100% of the votes polled. This move allows the company to transition from the SME segment to the main board, potentially enhancing liquidity and visibility for its shares.

In a parallel decision, shareholders sanctioned an application for the listing and trading of the company's shares on the Main Board of National Stock Exchange of India Limited. This resolution also secured unanimous approval from the votes cast. The dual approvals facilitate the company's shift to the main trading platforms of both premier stock exchanges in India.

The postal ballot process also saw the appointment of Mr. Sanat Bhat (DIN: 08059016) as an Independent Director for a period of 5 years. The resolution received 1,980,110 votes in favour, representing 100% of the total votes polled on this item. No votes were cast against the appointment.

Furthermore, Dr. Vinay Pandey (DIN: 10084203) was appointed as a Non-Executive Non-Independent Director, liable to retire by rotation. This ordinary resolution was passed with the support of 1,980,110 votes, constituting the entirety of the votes polled for this specific agenda item.

The voting results were submitted to BSE Limited pursuant to Regulation 44(3) of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015. The table below summarizes the voting outcomes for the key resolutions.

Sudarshan Pharma Industries Ltd has cancelled the meeting of its Board of Directors scheduled for June 18, 2026. The meeting was originally convened to consider and approve a proposal for raising funds through the issuance of various financial instruments. The cancellation was attributed to unavoidable reasons, as stated in a regulatory filing.

The Board had intended to evaluate the issuance of equity shares, convertible securities, warrants, or debt securities to bolster the company's capital base. The proposed fund-raising initiative was to be conducted through permissible methods such as private placement, preferential issue, qualified institutions placement, or a combination thereof.

Proposed Instruments and Methods

The company had outlined a broad spectrum of instruments for consideration. These included equity shares and convertible securities, which offer flexibility in structuring the capital raise. Additionally, the issuance of warrants and debt securities was on the table, providing multiple avenues to secure funding.

Regulatory Approvals

The implementation of the fund-raising proposal was subject to the receipt of necessary statutory and regulatory approvals. The meeting was held pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.